Alliancebernstein L.P. Arrowhead Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

  • $290 Billion
  • Q2 2025

A detailed history of Alliancebernstein L.P. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 159,070 shares of ARWR stock, worth $6.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
159,070
Previous 154,770 2.78%
Holding current value
$6.74 Million
Previous $1.97 Million 27.5%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$9.99 - $16.97 $42,957 - $72,971
4,300 Added 2.78%
159,070 $2.51 Million
Q1 2025

May 15, 2025
SELL
$12.74 - $21.53 $1.41 Million - $2.38 Million
-110,712 Reduced 41.7%
154,770 $1.97 Million
Q4 2024

Feb 12, 2025
SELL
$17.7 - $26.34 $7,805 - $11,615
-441 Reduced 0.17%
265,482 $4.99 Million
Q3 2024

Nov 14, 2024
SELL
$19.36 - $29.54 $177,260 - $270,468
-9,156 Reduced 3.33%
265,923 $5.15 Million
Q2 2024

Aug 14, 2024
BUY
$21.87 - $28.24 $682,912 - $881,822
31,226 Added 12.81%
275,079 $7.15 Million
Q1 2024

May 14, 2024
BUY
$27.21 - $39.48 $493,262 - $715,693
18,128 Added 8.03%
243,853 $6.97 Million
Q4 2023

Feb 14, 2024
SELL
$21.2 - $31.03 $22,705 - $33,233
-1,071 Reduced 0.47%
225,725 $6.91 Million
Q3 2023

Nov 14, 2023
SELL
$26.2 - $36.08 $119,183 - $164,127
-4,549 Reduced 1.97%
226,796 $6.09 Million
Q2 2023

Aug 15, 2023
SELL
$25.16 - $41.38 $1.81 Million - $2.97 Million
-71,841 Reduced 23.7%
231,345 $8.25 Million
Q1 2023

May 15, 2023
SELL
$23.68 - $38.51 $54 Million - $87.9 Million
-2,281,507 Reduced 88.27%
303,186 $7.7 Million
Q4 2022

Feb 14, 2023
BUY
$28.0 - $40.56 $3.29 Million - $4.77 Million
117,633 Added 4.77%
2,584,693 $105 Million
Q3 2022

Nov 15, 2022
SELL
$29.63 - $48.31 $9.81 Million - $16 Million
-331,074 Reduced 11.83%
2,467,060 $81.5 Million
Q2 2022

Aug 15, 2022
BUY
$27.79 - $50.61 $1.16 Million - $2.12 Million
41,803 Added 1.52%
2,798,134 $98.5 Million
Q1 2022

May 13, 2022
BUY
$39.62 - $69.97 $11.6 Million - $20.4 Million
291,820 Added 11.84%
2,756,331 $127 Million
Q4 2021

Feb 14, 2022
BUY
$58.09 - $82.51 $86.8 Million - $123 Million
1,494,218 Added 154.0%
2,464,511 $163 Million
Q3 2021

Nov 10, 2021
SELL
$58.38 - $84.96 $8.56 Million - $12.5 Million
-146,587 Reduced 13.12%
970,293 $60.6 Million
Q2 2021

Jul 30, 2021
BUY
$62.15 - $90.32 $3.16 Million - $4.6 Million
50,883 Added 4.77%
1,116,880 $92.5 Million
Q1 2021

May 06, 2021
BUY
$61.35 - $90.47 $46.6 Million - $68.8 Million
760,005 Added 248.37%
1,065,997 $70.7 Million
Q4 2020

Feb 08, 2021
SELL
$43.82 - $85.37 $550,379 - $1.07 Million
-12,560 Reduced 3.94%
305,992 $23.5 Million
Q3 2020

Nov 12, 2020
SELL
$33.21 - $51.27 $1.22 Million - $1.88 Million
-36,718 Reduced 10.34%
318,552 $13.7 Million
Q2 2020

Aug 13, 2020
BUY
$26.12 - $43.27 $834,795 - $1.38 Million
31,960 Added 9.89%
355,270 $15.3 Million
Q1 2020

May 14, 2020
SELL
$20.56 - $63.12 $140,013 - $429,847
-6,810 Reduced 2.06%
323,310 $9.3 Million
Q4 2019

Feb 18, 2020
BUY
$28.14 - $73.01 $2.36 Million - $6.12 Million
83,850 Added 34.05%
330,120 $20.9 Million
Q3 2019

Nov 14, 2019
SELL
$26.26 - $34.86 $527,826 - $700,686
-20,100 Reduced 7.55%
246,270 $6.94 Million
Q2 2019

Aug 14, 2019
BUY
$17.43 - $28.82 $2.7 Million - $4.47 Million
154,998 Added 139.17%
266,370 $7.06 Million
Q1 2019

May 14, 2019
SELL
$12.05 - $20.18 $220,852 - $369,859
-18,328 Reduced 14.13%
111,372 $2.04 Million
Q3 2018

Nov 08, 2018
BUY
$14.0 - $20.3 $373,800 - $542,010
26,700 Added 25.92%
129,700 $2.49 Million
Q2 2018

Aug 13, 2018
BUY
$6.37 - $14.02 $656,110 - $1.44 Million
103,000 New
103,000 $1.4 Million

Others Institutions Holding ARWR

# of Institutions
328
Shares Held
99.7M
Call Options Held
444K
Put Options Held
568K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $4.49B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email